We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ERWINASE (PPD Australia Pty Ltd)
Product name
ERWINASE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
228 (255 working days)
Active ingredients
crisantaspase
Registration type
NCE/NBE
Indication
ERWINASE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to pegylated asparaginase obtained from E. coli.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.